CHMP recommends higher dose of Novo Nordisk's Ozempic

The EMA's expert committee, the CHMP, has reported a positive opinion of Novo Nordisk's application to extend the marketing its diabetes drug Ozempic to a new dose of 2.0 mg.


A new version of Novo Nordisk's once-weekly diabetes drug Ozempic looks to be on the road to European patients, the pharmaceutical company reports in a press release.

Novo Nordisk thus announces on Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has suggested that Ozempic be approved in a new dose of its active ingredient of 2.0 mg. Ozempic, which is a GLP-1 analog, is used in the treatment of diabetes patients with type 2 diabetes, which is already approved in the doses of 0.5 mg and 1.0 mg.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs